APO Research
Talk to an analyst

APO RESEARCH · REPORT

Onychomycosis (Tinea Unguium) Drug

Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate.

Onychomycosis (Tinea Unguium) Drug is the drug for the treatment of the disease.

Selected research

Market Outlook & Growth Opportunities

Global Onychomycosis (Tinea Unguium) Drug Market Outlook and Growth Opportunities 2026

21 December 2025199 pages

Choose your research edition.

Industry ResearchOnychomycosis (Tinea Unguium) Drug Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Onychomycosis (Tinea Unguium) Drug Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Onychomycosis (Tinea Unguium) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Onychomycosis (Tinea Unguium) Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Onychomycosis (Tinea Unguium) Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate.

Onychomycosis (Tinea Unguium) Drug is the drug for the treatment of the disease.

Global Onychomycosis (Tinea Unguium) Drug key players include Pfizer, J&J, Novartis, Galderma pharm, Valeant Pharma, etc. Global top five manufacturers hold a share about 35%.

Read the full market overview

North America is the largest market, with a share about 30%, followed by Europe and China both have a share over 45 percent.

In terms of product, Oral Medication is the largest segment, with a share over 70%. And in terms of application, the largest application is Age above 50, followed by Age under 18.

This report provides an overview of the global Onychomycosis (Tinea Unguium) Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Onychomycosis (Tinea Unguium) Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Onychomycosis (Tinea Unguium) Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Onychomycosis (Tinea Unguium) Drug market.

Onychomycosis (Tinea Unguium) Drug Segment by Company

Pfizer

Yangtze River

Torrent Pharma

J&J

Chengdu Brilliant

Novartis

Qilu Pharmaceutical

Xiuzheng Pharmaceutical

Hubei Hengan

TARO

Perrigo

Galderma pharm

Zhejiang Deyer

Valeant Pharma

Moberg

Onychomycosis (Tinea Unguium) Drug Segment by Type

Oral Medication

External Medicine

Onychomycosis (Tinea Unguium) Drug Segment by Application

Age under 18

Age 18-50

Age above 50

Onychomycosis (Tinea Unguium) Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Onychomycosis (Tinea Unguium) Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Onychomycosis (Tinea Unguium) Drug key companies, revenue, market share, and recent developments.

3. To split the Onychomycosis (Tinea Unguium) Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Onychomycosis (Tinea Unguium) Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Onychomycosis (Tinea Unguium) Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Onychomycosis (Tinea Unguium) Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Onychomycosis (Tinea Unguium) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Onychomycosis (Tinea Unguium) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Onychomycosis (Tinea Unguium) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Onychomycosis (Tinea Unguium) Drug industry.

Chapter 3: Detailed analysis of Onychomycosis (Tinea Unguium) Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Onychomycosis (Tinea Unguium) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Onychomycosis (Tinea Unguium) Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Onychomycosis (Tinea Unguium) Drug Industry Trends Table 2. Onychomycosis (Tinea Unguium) Drug Industry Drivers Table 3. Onychomycosis (Tinea Unguium) Drug Industry Opportunities and Challenges Table 4. Onychomycosis (Tinea Unguium) Drug Industry Restraints Table 5. Global Onychomycosis (Tinea Unguium) Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Onychomycosis (Tinea Unguium) Drug Revenue Share by Company (2021-2026) Table 7. Global Onychomycosis (Tinea Unguium) Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Onychomycosis (Tinea Unguium) Drug Key Company Manufacturing Base & Headquarters Table 9. Global Onychomycosis (Tinea Unguium) Drug Company, Product Type & Application Table 10. Global Onychomycosis (Tinea Unguium) Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Onychomycosis (Tinea Unguium) Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Oral Medication Table 15. Significant Companies of External Medicine Table 16. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type (2021-2026) Table 20. Global Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Age under 18 Table 22. Significant Companies of Age 18-50 Table 23. Significant Companies of Age above 50 Table 24. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application (2021-2026) Table 28. Global Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application (2027-2032) Table 29. Global Onychomycosis (Tinea Unguium) Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Onychomycosis (Tinea Unguium) Drug Sales Value Share by Region (2021-2026) Table 32. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Onychomycosis (Tinea Unguium) Drug Sales Value Share by Region (2027-2032) Table 34. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Onychomycosis (Tinea Unguium) Drug Sales Value Market Share by Country (2021-2026) Table 37. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Onychomycosis (Tinea Unguium) Drug Sales Value Market Share by Country (2027-2032) Table 39. Pfizer Company Information Table 40. Pfizer Business Overview Table 41. Pfizer Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Pfizer Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 43. Pfizer Recent Development Table 44. Yangtze River Company Information Table 45. Yangtze River Business Overview Table 46. Yangtze River Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Yangtze River Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 48. Yangtze River Recent Development Table 49. Torrent Pharma Company Information Table 50. Torrent Pharma Business Overview Table 51. Torrent Pharma Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Torrent Pharma Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 53. Torrent Pharma Recent Development Table 54. J&J Company Information Table 55. J&J Business Overview Table 56. J&J Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. J&J Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 58. J&J Recent Development Table 59. Chengdu Brilliant Company Information Table 60. Chengdu Brilliant Business Overview Table 61. Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 63. Chengdu Brilliant Recent Development Table 64. Novartis Company Information Table 65. Novartis Business Overview Table 66. Novartis Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Novartis Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 68. Novartis Recent Development Table 69. Qilu Pharmaceutical Company Information Table 70. Qilu Pharmaceutical Business Overview Table 71. Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 73. Qilu Pharmaceutical Recent Development Table 74. Xiuzheng Pharmaceutical Company Information Table 75. Xiuzheng Pharmaceutical Business Overview Table 76. Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 78. Xiuzheng Pharmaceutical Recent Development Table 79. Hubei Hengan Company Information Table 80. Hubei Hengan Business Overview Table 81. Hubei Hengan Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Hubei Hengan Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 83. Hubei Hengan Recent Development Table 84. TARO Company Information Table 85. TARO Business Overview Table 86. TARO Onychomycosis (Tinea Unguium) Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. TARO Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 88. TARO Recent Development Table 89. Perrigo Company Information Table 90. Perrigo Business Overview Table 91. Perrigo Onychomycosis (Tinea Unguium) Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Perrigo Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 93. Perrigo Recent Development Table 94. Galderma pharm Company Information Table 95. Galderma pharm Business Overview Table 96. Galderma pharm Onychomycosis (Tinea Unguium) Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Galderma pharm Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 98. Galderma pharm Recent Development Table 99. Zhejiang Deyer Company Information Table 100. Zhejiang Deyer Business Overview Table 101. Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 103. Zhejiang Deyer Recent Development Table 104. Valeant Pharma Company Information Table 105. Valeant Pharma Business Overview Table 106. Valeant Pharma Onychomycosis (Tinea Unguium) Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Valeant Pharma Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 108. Valeant Pharma Recent Development Table 109. Moberg Company Information Table 110. Moberg Business Overview Table 111. Moberg Onychomycosis (Tinea Unguium) Drug Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Moberg Onychomycosis (Tinea Unguium) Drug Product Portfolio Table 113. Moberg Recent Development Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Onychomycosis (Tinea Unguium) Drug Product Image Figure 2. Global Onychomycosis (Tinea Unguium) Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Onychomycosis (Tinea Unguium) Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Onychomycosis (Tinea Unguium) Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Oral Medication Image Figure 8. External Medicine Image Figure 9. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Onychomycosis (Tinea Unguium) Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type (2021-2032) Figure 12. Age under 18 Image Figure 13. Age 18-50 Image Figure 14. Age above 50 Image Figure 15. Global Onychomycosis (Tinea Unguium) Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Onychomycosis (Tinea Unguium) Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application (2021-2032) Figure 18. Global Onychomycosis (Tinea Unguium) Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Onychomycosis (Tinea Unguium) Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Onychomycosis (Tinea Unguium) Drug Sales Value (2021-2032) & (US$ Million) Figure 21. North America Onychomycosis (Tinea Unguium) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Onychomycosis (Tinea Unguium) Drug Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Onychomycosis (Tinea Unguium) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Onychomycosis (Tinea Unguium) Drug Sales Value (2021-2032) & (US$ Million) Figure 27. South America Onychomycosis (Tinea Unguium) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Medication
  • External Medicine
Applications
  • Age under 18
  • Age 18-50
  • Age above 50
Companies covered
  • Pfizer
  • Yangtze River
  • Torrent Pharma
  • J&J
  • Chengdu Brilliant
  • Novartis
  • Qilu Pharmaceutical
  • Xiuzheng Pharmaceutical
  • Hubei Hengan
  • TARO
  • Perrigo
  • Galderma pharm
  • Zhejiang Deyer
  • Valeant Pharma
  • Moberg

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Onychomycosis (Tinea Unguium) Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Onychomycosis (Tinea Unguium) Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Onychomycosis (Tinea Unguium) Drug Market Dynamics
  1. 2.1 Onychomycosis (Tinea Unguium) Drug Industry Trends
  2. 2.2 Onychomycosis (Tinea Unguium) Drug Industry Drivers
  3. 2.3 Onychomycosis (Tinea Unguium) Drug Industry Opportunities and Challenges
  4. 2.4 Onychomycosis (Tinea Unguium) Drug Industry Restraints
3 Onychomycosis (Tinea Unguium) Drug Market by Company
  1. 3.1 Global Onychomycosis (Tinea Unguium) Drug Company Revenue Ranking in 2025
  2. 3.2 Global Onychomycosis (Tinea Unguium) Drug Revenue by Company (2021-2026)
  3. 3.3 Global Onychomycosis (Tinea Unguium) Drug Company Ranking (2024-2026)
  4. 3.4 Global Onychomycosis (Tinea Unguium) Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Onychomycosis (Tinea Unguium) Drug Company Product Type and Application
  6. 3.6 Global Onychomycosis (Tinea Unguium) Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Onychomycosis (Tinea Unguium) Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Onychomycosis (Tinea Unguium) Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Onychomycosis (Tinea Unguium) Drug Market by Type
  1. 4.1 Onychomycosis (Tinea Unguium) Drug Type Introduction
  2. 4.1.1 Oral Medication
  3. 4.1.2 External Medicine
  4. 4.2 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Type
  5. 4.2.1 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Type (2021-2032)
  7. 4.2.3 Global Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type (2021-2032)
5 Onychomycosis (Tinea Unguium) Drug Market by Application
  1. 5.1 Onychomycosis (Tinea Unguium) Drug Application Introduction
  2. 5.1.1 Age under 18
  3. 5.1.2 Age 18-50
  4. 5.1.3 Age above 50
  5. 5.2 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Application
  6. 5.2.1 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application (2021-2032)
6 Onychomycosis (Tinea Unguium) Drug Regional Value Analysis
  1. 6.1 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Onychomycosis (Tinea Unguium) Drug Sales Value (2021-2032)
  7. 6.3.2 North America Onychomycosis (Tinea Unguium) Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Onychomycosis (Tinea Unguium) Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Onychomycosis (Tinea Unguium) Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Onychomycosis (Tinea Unguium) Drug Sales Value (2021-2032)
  16. 6.6.2 South America Onychomycosis (Tinea Unguium) Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Sales Value Share by Country, 2025 VS 2032
7 Onychomycosis (Tinea Unguium) Drug Country-level Value Analysis
  1. 7.1 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Onychomycosis (Tinea Unguium) Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Onychomycosis (Tinea Unguium) Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Onychomycosis (Tinea Unguium) Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Onychomycosis (Tinea Unguium) Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Onychomycosis (Tinea Unguium) Drug Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 Yangtze River
  8. 8.2.1 Yangtze River Company Information
  9. 8.2.2 Yangtze River Business Overview
  10. 8.2.3 Yangtze River Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Yangtze River Onychomycosis (Tinea Unguium) Drug Product Portfolio
  12. 8.2.5 Yangtze River Recent Developments
  13. 8.3 Torrent Pharma
  14. 8.3.1 Torrent Pharma Company Information
  15. 8.3.2 Torrent Pharma Business Overview
  16. 8.3.3 Torrent Pharma Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Torrent Pharma Onychomycosis (Tinea Unguium) Drug Product Portfolio
  18. 8.3.5 Torrent Pharma Recent Developments
  19. 8.4 J&J
  20. 8.4.1 J&J Company Information
  21. 8.4.2 J&J Business Overview
  22. 8.4.3 J&J Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 J&J Onychomycosis (Tinea Unguium) Drug Product Portfolio
  24. 8.4.5 J&J Recent Developments
  25. 8.5 Chengdu Brilliant
  26. 8.5.1 Chengdu Brilliant Company Information
  27. 8.5.2 Chengdu Brilliant Business Overview
  28. 8.5.3 Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Product Portfolio
  30. 8.5.5 Chengdu Brilliant Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Onychomycosis (Tinea Unguium) Drug Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Qilu Pharmaceutical
  38. 8.7.1 Qilu Pharmaceutical Company Information
  39. 8.7.2 Qilu Pharmaceutical Business Overview
  40. 8.7.3 Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Product Portfolio
  42. 8.7.5 Qilu Pharmaceutical Recent Developments
  43. 8.8 Xiuzheng Pharmaceutical
  44. 8.8.1 Xiuzheng Pharmaceutical Company Information
  45. 8.8.2 Xiuzheng Pharmaceutical Business Overview
  46. 8.8.3 Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Product Portfolio
  48. 8.8.5 Xiuzheng Pharmaceutical Recent Developments
  49. 8.9 Hubei Hengan
  50. 8.9.1 Hubei Hengan Company Information
  51. 8.9.2 Hubei Hengan Business Overview
  52. 8.9.3 Hubei Hengan Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hubei Hengan Onychomycosis (Tinea Unguium) Drug Product Portfolio
  54. 8.9.5 Hubei Hengan Recent Developments
  55. 8.10 TARO
  56. 8.10.1 TARO Company Information
  57. 8.10.2 TARO Business Overview
  58. 8.10.3 TARO Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 TARO Onychomycosis (Tinea Unguium) Drug Product Portfolio
  60. 8.10.5 TARO Recent Developments
  61. 8.11 Perrigo
  62. 8.11.1 Perrigo Company Information
  63. 8.11.2 Perrigo Business Overview
  64. 8.11.3 Perrigo Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Perrigo Onychomycosis (Tinea Unguium) Drug Product Portfolio
  66. 8.11.5 Perrigo Recent Developments
  67. 8.12 Galderma pharm
  68. 8.12.1 Galderma pharm Company Information
  69. 8.12.2 Galderma pharm Business Overview
  70. 8.12.3 Galderma pharm Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Galderma pharm Onychomycosis (Tinea Unguium) Drug Product Portfolio
  72. 8.12.5 Galderma pharm Recent Developments
  73. 8.13 Zhejiang Deyer
  74. 8.13.1 Zhejiang Deyer Company Information
  75. 8.13.2 Zhejiang Deyer Business Overview
  76. 8.13.3 Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Product Portfolio
  78. 8.13.5 Zhejiang Deyer Recent Developments
  79. 8.14 Valeant Pharma
  80. 8.14.1 Valeant Pharma Company Information
  81. 8.14.2 Valeant Pharma Business Overview
  82. 8.14.3 Valeant Pharma Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Valeant Pharma Onychomycosis (Tinea Unguium) Drug Product Portfolio
  84. 8.14.5 Valeant Pharma Recent Developments
  85. 8.15 Moberg
  86. 8.15.1 Moberg Company Information
  87. 8.15.2 Moberg Business Overview
  88. 8.15.3 Moberg Onychomycosis (Tinea Unguium) Drug Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Moberg Onychomycosis (Tinea Unguium) Drug Product Portfolio
  90. 8.15.5 Moberg Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst